• Kazuhisa Tsuruta, Yoshinobu Yamada, Masashi Serada, and Yusuke Tanigawara.
• Clinical Development Center, Asahi Kasei Pharma Co. Ltd., 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101, Japan. tsuruta.kb@om.asahi-kasei.co.jp
• J Clin Pharmacol. 2011 Sep 1;51(9):1276-85.

AbstractThrombomodulin alfa is the recombinant extracellular domain of human thrombomodulin, which shows anticoagulation activity. To elucidate the pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation (DIC), population pharmacokinetic (PPK) analysis was performed using plasma concentration data obtained in phase 1 (20 patients, 348 time points) and phase 2 (116 patients, 305 time points) clinical trials. The actual and predicted plasma concentrations of thrombomodulin alfa based on the final PPK model showed a good linear correlation (R = 0.9504), and the pharmacokinetics of thrombomodulin alfa in DIC patients were affected by body weight, age, renal dysfunction, and hematocrit value. The distribution volume and clearance (CL) were proportional to body weight and were significantly increased in patients with lower hematocrit value (male <40%, female <35%). Furthermore, CL was decreased in patients with renal dysfunction and in elderly patients. Based on these results, the standard dose of thrombomodulin alfa is adjusted according to body weight. However, further dose adjustment is not needed based on age and hematocrit value, since these factors did not cause the large changes in plasma concentration that can affect the efficacy or safety.

23 keywords...

hide…